Tokyo, April 11 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000061224) titled 'Comparison of outpatient visit patterns for renal anemia in patients with chronic kidney disease' on April 11.
Study Type:
Observational
Primary Sponsor:
Institute - The University of Tokyo Hospital
Condition:
Condition - renal anemia
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - HIF-PH inhibitors are administered orally, whereas erythropoiesis-stimulating agents (ESAs) require subcutaneous injection. These differences may affect outpatient clinical workflow, as well as outpatient visit frequency, outpatient visit duration, and drug-related costs. This retrospective observational study aims to compare outpatient visit frequency, outpatient visit duration, and drug-related costs between patients receiving HIF-PH inhibitors and those receiving ESAs among patients with non-dialysis chronic kidney disease (CKD).
Basic objectives2 - Others
Eligibility:
Age-lower limit - 15
years-old
Gender - Male and Female
Key inclusion criteria - Patients with non-dialysis chronic kidney disease (CKD) who attended the outpatient department of the Department of Nephrology and Endocrinology at the University of Tokyo Hospital between January 1, 2022 and December 31, 2025, and who received or were prescribed erythropoiesis-stimulating agents (ESAs) or HIF-PH inhibitors during the observation period.
Key exclusion criteria - Patients who were considered inappropriate for inclusion in the study by the investigators, or who declined the use of their information for research purposes.
Target Size - 300
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 03 Month 31 Day
Date of IRB - 2026 Year 03 Month 31 Day
Anticipated trial start date - 2026 Year 04 Month 11 Day
Last follow-up date - 2030 Year 12 Month 31 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000070058
Disclaimer: Curated by HT Syndication.